Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Items 301–400 of 1,000
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
Patrinely, J. R., McGuigan, B., Chandra, S., Fenton, S. E., Chowdhary, A., Kennedy, L. B., Mooradian, M. J., Palmeri, M., Portal, D., Horst, S. N., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1875639 · Cited by 64
“We observed a higher rate of severe (21%) extrahepatic toxicities than previously described.(20,21) While combination therapy with CTLA4 inhibitors has been known to increase the risk of severe irAEs, we found that combination therapy did not predict hepatitis severity, the need for second-line immunosuppressants, or…”
ResultSelf-citationMelanoma and Immune Checkpoint Inhibitors
Furue, M., Ito, T., Wada, N. A., Wada, M., Kadono, T., & Uchi, H. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0676-z · Cited by 71
Baxi, V., Lee, G., Duan, C., Pandya, D., Cohen, D. N., Edwards, R., Chang, H., Li, J., Elliott, H., Pokkalla, H., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01119-2 · Cited by 66
Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
Herrscher, H., & Robert, C. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000610 · Cited by 79
Tarhini, A., Lin, Y., Lin, H., Rahman, Z., Vallabhaneni, P., Mendiratta, P., Pingpank, J. F., Holtzman, M. P., Yusko, E. C., Rytlewski, J. A., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0428-5 · Cited by 63
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 80
Santo, C. D., Cheng, P., Beggs, A. D., Egan, S. A., Bessudo, A., & Mussai, F. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0612-6 · Cited by 65
“Current treatment strategies for high-stage melanoma are based around the use of immunotherapy with immune checkpoint inhibitors such as anti-PDL1 or anti-CTLA4 antibodies to stimulate anti-cancer T cell responses, or signal-transduction inhibitors such as those targeting BRAF and MEK pathways [3, 4].”
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Bhave, P., Pallan, L., Long, G. V., Menzies, A. M., Atkinson, V. G., Cohen, J. V., Sullivan, R. J., Chiarion‐Sileni, V., Nyakas, M., Kähler, K. C., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01121-y · Cited by 86
Self-citationBroman, K. K., Hughes, T. M., Dossett, L. A., Sun, J. X., Kirichenko, D., Carr, M. J., Sharma, A. S., Bartlett, E. K., Nijhuis, A. A. G., Thompson, J. F., et al. (2021) · Cancer · doi:10.1002/cncr.33483 · Cited by 64
“Presence of microsatellites 59 (10) 41 (10) .”
Xie, W., Chen, B., Wen, H., Xiao, P., Wang, L., Liu, W., Wang, D., & Tang, B. Z. (2022) · ACS Nano · doi:10.1021/acsnano.2c02605 · Cited by 67
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
Brastianos, P. K., Kim, A. E., Giobbie‐Hurder, A., Lee, E. Q., Lin, N., Overmoyer, B. A., Wen, P. Y., Nayak, L., Cohen, J. V., Dietrich, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02392-7 · Cited by 67
Clinical characterization of colitis arising from anti-PD-1 based therapy
Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R. J., Silk, A. W., Zhou, A. Y., Compton, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1524695 · Cited by 69
Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition
Bajaj, S., Donnelly, D. M., Call, M., Johannet, P. M., Moran, U., Polsky, D., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Weber, J. S., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa008 · Cited by 65
Self-citationKanaki, T., Stang, A., Gutzmer, R., Zimmer, L., Chorti, E., Sucker, A., Ugurel, S., Hadaschik, E. N., Gräger, N., Satzger, I., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.011 · Cited by 62
Insights into non-classic and emerging causes of hypopituitarism
Prodam, F., Caputo, M., Mele, C., Marzullo, P., & Aimaretti, G. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00437-2 · Cited by 71
Wieland, A., Kamphorst, A. O., Adsay, V. N., Masor, J. J., Sarmiento, J. M., Nasti, T. H., Darko, S. W., Douek, D. C., Xue, Y., Curran, W. J., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2228-7 · Cited by 67
Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
Self-citationLü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 66
Amaral, T. M. S., Hoffmann, M., Sinnberg, T. W., Niessner, H., Sülberg, H., Eigentler, T., & Garbe, C. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.027 · Cited by 64
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 67
Amato, C. M., Hintzsche, J. D., Wells, K. R., Applegate, A. J., Gorden, N. T., Vorwald, V. M., Tobin, R. P., Nassar, K. W., Shellman, Y. G., Kim, J., et al. (2020) · Cancers · doi:10.3390/cancers12071943 · Cited by 66
Self-citationCurrent status of immunotherapy for advanced gastric cancer
Kawazoe, A., Shitara, K., Boku, N., Yoshikawa, T., & Terashima, M. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa202 · Cited by 67
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 64
Goldinger, S. M., Buder‐Bakhaya, K., Lo, S., Forschner, A., McKean, M. A., Zimmer, L., Khoo, C. C. H., Dummer, R., Eroglu, Z., Buchbinder, E. I., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.022 · Cited by 71
Self-citationVulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature
Boer, F. L., Eikelder, M. T., Kapiteijn, E., Creutzberg, C. L., Galaal, K. A., & van Poelgeest, M. I. E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.005 · Cited by 71
Preferences for Immunotherapy in Melanoma: A Systematic Review
Livingstone, A., Agarwal, A. A., Stockler, M. R., Menzies, A. M., Howard, K., & Morton, R. L. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07963-y · Cited by 64
Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
Boonstra, P. A., Wind, T. T., van Kruchten, M., Schuuring, E. M. D., Hospers, G. A. P., van der Wekken, A. J., de Groot, D. J. A., Schröder, C. P., Fehrmann, R. S. N., & Reyners, A. K. L. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09876-9 · Cited by 75
“Conversely, of the patients with “true” progression (n = 20), 90% had stable or increasing ctDNA levels compared with pre-treatment levels after 12 weeks of ICI therapy.”
BackgroundInfluentialMalignant Melanoma: Diagnostic and Management Update
Knackstedt, T., Knackstedt, R. W., Couto, R. A., & Gastman, B. (2018) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000004571 · Cited by 67
Anderson, R. A., Clatot, F., Demeestere, I., Lambertini, M., Morgan, A. A., Nelson, S. M., Peccatori, F. A., & Cameron, D. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.032 · Cited by 63
Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma
Mason, R., Dearden, H. C., Nguyen, B., Soon, J. A., Smith, J. L., Randhawa, M., Mant, A. M., Warburton, L., Lo, S., Meniawy, T. M., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12831 · Cited by 60
“…improving survival for not only those with advanced disease, but also those at high risk of recurrence (Ascierto et al., 2016; Eggermont et al., 2018; Larkin et al., 2015; Long, Flaherty, et al., 2017; Long, Hauschild, et al., 2017; Schachter et al., 2017; Weber et al., 2017; Wolchok et al., 2017).”
BackgroundSelf-citationIgnatiadis, M., Bailey, A., McArthur, H. L., El-Abed, S., de Azambuja, E., Metzger, O., Chui, S. Y., Dieterich, M., Perretti, T., Shearer-Kang, E., et al. (2025) · JAMA · doi:10.1001/jama.2024.26886 · Cited by 78
Cancer immunotherapy-associated hypophysitis
Solinas, C., Porcu, M., Silva, P. D., Musi, M., Aspeslagh, S., Scartozzi, M., Willard-Gallo, K. E., Mariotti, S., & Saba, L. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.09.002 · Cited by 63
Systemic Therapies for Advanced Melanoma
Bomar, L., Senthilnathan, A., & Ahn, C. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2019.05.001 · Cited by 63
Zhao, P., Qiu, L., Zhou, S., Li, L., Qian, Z., & Zhang, H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s295565 · Cited by 61
Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V. G., Mandalà, M., Chiarion‐Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30940-9 · Cited by 58
Self-citationPrinciples of Targeted Therapy for Melanoma
Sun, J. X., Carr, M. J., & Khushalani, N. I. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.013 · Cited by 63
Kim, K. H., Hur, J. Y., Cho, J., Ku, B. M., Koh, J., Koh, J., Sun, J., Lee, S., Ahn, J. S., Park, K., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722023 · Cited by 68
Eggermont, A. M. M., & Dummer, R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.014 · Cited by 59
Association Between Melanoma Detected During Routine Skin Checks and Mortality
Watts, C. G., McLoughlin, K. G., Goumas, C., van Kemenade, C. H., Aitken, J. F., Soyer, H. P., Fernández‐Peñas, P., Guitera, P., Scolyer, R. A., Morton, R. L., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.3884 · Cited by 74
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial
Bol, K. F., Schreibelt, G., Bloemendal, M., van Willigen, W. W., Bree, S. H.-D., de Goede, A. L., de Boer, A. J., Bos, K., Boer, T. D., Nordkamp, M. A. M. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45358-0 · Cited by 66
Immuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 68
Wright, F. C., Souter, L., Kellett, S., Easson, A. M., Murray, C., Toye, J., McCready, D. R., Nessim, C., Ghazarian, D., Hong, N. J. L., et al. (2019) · Current Oncology · doi:10.3747/co.26.4885 · Cited by 58
Giannini, E. G., Aglitti, A., Borzio, M., Gambato, M., Guarino, M., Iavarone, M. A., Lai, Q., Sandri, G. B. L., Melandro, F., Morisco, F., et al. (2019) · Cancers · doi:10.3390/cancers11111689 · Cited by 63
“In both settings of surgery and locoregional treatment, treatment-induced liberation of tumour-associated antigens has previously been demonstrated, thus providing a strong rationale for a combined treatment with immunostimulating agents, as previously shown for other solid tumours [79].”
ResultThe Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies
Keung, E. Z.-Y., Ukponmwan, E. U., Cogdill, A. P., & Wargo, J. A. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6379-8 · Cited by 59
Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors
Gault, A., Anderson, A. E., Plummer, R., Stewart, C. J., Pratt, A. G., & Rajan, N. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19750 · Cited by 98
Bacterial outer membrane vesicle-based cancer nanovaccines
Gao, X., Feng, Q., Wang, J., & Zhao, X. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0452 · Cited by 64
“Five key aspects must be developed and investigated when OMVs are used as tumor vaccine vectors (Figure 2): (1) strain selection; (2) heterogeneity of OMVs; (3) tumor antigen loading; (4) immunogenicity and safety of OMVs; and (5) mass production of OMVs.”
BackgroundInfluentialNeoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
Ho, J., Mattei, J., Tetzlaff, M. T., Williams, M. D., Davies, M. A., Diab, A. K., Oliva, I. C. G., McQuade, J. L., Patel, S. P., Tawbi, H. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1001150 · Cited by 59
“For example, CHECKMATE 238 included 29 (3%) patients with MM and the subgroup analysis did not show better outcome with either adjuvant nivolumab or ipilimumab (18).”
BackgroundTherapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 62
“…C. 19 (95% CI: 14.9–23.8) A. 11.5 B. 8.9 C. 2.2 A. 55.0 B. 16.3 C. 27.3 Expanded indication: unresectable or metastatic melanoma regardless of BRAF V600 mutation status (January 2016) Weber et al. (2017) [146] CheckMate 238 III Completely resected,advanced disease A. Nivolumab 3mg/kg Q2wks.”
InfluentialConsidering adjuvant therapy for stage II melanoma
Poklepovic, A. S., & Luke, J. J. (2019) · Cancer · doi:10.1002/cncr.32585 · Cited by 62
Mulder, E. E. A. P., Dwarkasing, J. T., Tempel, D., Spek, A., Bosman, L., Verver, D., Mooyaart, A. L., van der Veldt, A. A. M., Verhoef, C. K., Nijsten, T. E. C., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19499 · Cited by 56
“8,9,28,33 12 – 14 Therefore, it is expected that the number of patients with melanoma who undergo SLNB will increase.”
BackgroundTherapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Attrill, G. H., Owen, C. N., Ahmed, T., Vergara, I. A., Colebatch, A. J., Conway, J. W., Nahar, K. J., Thompson, J. F., da Silva, I. P., Carlino, M. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004771 · Cited by 64
Self-citationImmunotherapy for Merkel cell carcinoma: a turning point in patient care
Chan, I. S., Bhatia, S., Kaufman, H. L., & Lipson, E. J. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0335-9 · Cited by 55
Self-citationGajiwala, S., Torgeson, A. M., Garrido‐Laguna, I., Kinsey, C. G., & Lloyd, S. A. J. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.16 · Cited by 56
“Clinical utilization of immune checkpoint inhibitors has been examined in adjuvant treatment for curable disease (7-9), first-line therapy for recurrent disease or initial metastatic failure (10,11), or second-line therapy in metastatic disease refractory to other treatment options (12,13).”
BackgroundWADA-OHNO, M., Ito, T., & Furue, M. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0666-x · Cited by 60
Ferreira, J. L., Costa, C. F., Marques, B., Castro, S., Víctor, M., Oliveira, J., Santos, A. P., Sampaio, I. L., Duarte, H., Marques, A. P., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02664-y · Cited by 59
Hall, E. T., Singhal, S., Dickerson, J. C., Gabster, B. P., Wong, H.-N., Aslakson, R. A., Schapira, L., Aslakson, R. A., Ast, K., Carroll, T., et al. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.03.015 · Cited by 59
Albittar, A. A., Alhalabi, O., & Oliva, I. C. G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_3 · Cited by 62
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
Salzmann, M., Tosev, G., Heck, M., Schadendorf, D., Maatouk, I., Enk, A., Hartmann, M., & Hassel, J. C. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.031 · Cited by 58
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 61
“NCT02388906 3 Nivolumab vs ipilimumab [66] NCT01704287 2 Pembrolizumab vs dacarbazine or carboplatin plus paclitaxel or paclitaxel or temozolomide [68]”
BackgroundUpdate on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 56
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers
Telli, T. A., Bregni, G., Camera, S., Deleporte, A., Hendlisz, A., & Sclafani, F. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.036 · Cited by 56
Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma
Delgado, A. F., Zommorodi, S., & Delgado, A. F. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0798-y · Cited by 54
Next-generation cancer vaccines and emerging immunotherapy combinations
Brandenburg, A., Heine, A., & Brossart, P. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.003 · Cited by 58
Exosome-based immunotherapy as an innovative therapeutic approach in melanoma
Babaei, S., Fadaee, M., Abbasi-kenarsari, H., Shanehbandi, D., & Kazemi, T. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01906-1 · Cited by 48
“14 .4% of patients treated in the nivolumab arm and 45.9% in the ipilim-umab arm experienced grade 3/4 adverse events, leading to termination rates of 3.5% and 30.0%, respectively [65].”
BackgroundInfluentialBurotto, M., Wilkerson, J., Stein, W. D., Bates, S. E., & Fojo, T. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.01.002 · Cited by 55
Vulvar malignancies: an interdisciplinary perspective
Wohlmuth, C., & Wieser, I. (2019) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13995 · Cited by 74
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
Mittendorf, E. A., Burgers, F. H., Haanen, J. B. A. G., & Cascone, T. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349411 · Cited by 61
Recent advancements in esophageal cancer treatment in Japan
Tanaka, Y., Yoshida, K., Suetsugu, T., Imai, T., Matsuhashi, N., & Yamaguchi, K. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12174 · Cited by 52
Malissen, N., Macagno, N., Granjeaud, S., Granier, C., Moutardier, V., Gaudy‐Marqueste, C., Habel, N., Mandavit, M., Guillot, B., Pasero, C., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1665976 · Cited by 59
“Cohort 116 65 (56) 51 (44) Men 65 31 (48) 34 (52) Women 51 34 (67) 17 (33) Median age at initial diagnostic [range] 56 [19-89] 54 [25-86]”
Self-citationExpanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function
Mullinax, J. E., Hall, M. S., Beatty, M. S., Weber, A. M., Sannasardo, Z., Svrdlin, T., Hensel, J. A., Bui, M. M., Richards, A. D., González, R., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000355 · Cited by 55
Fu, J., Li, W.-Z., McGrath, N. A., Lai, C. W., Brar, G., Xiang, Y.-Q., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 51
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
Trojaniello, C., Luke, J. J., & Ascierto, P. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670726 · Cited by 58
“A phase III clinical trial, the CheckMate 238, has compared nivolumab at a dosage of 3 mg/kg every 2 weeks for 1 year in patients with completely resected stage IIIB/C or IV with ipilimumab at a dosage of 10 mg/kg every 3 weeks (Q3W) for 4 doses and every 12 weeks thereafter for 1 year in the adjuvant setting (21).”
MethodSelf-citationPersonalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019
Nakamura, Y., Asai, J., Igaki, H., Inozume, T., Namikawa, K., Hayashi, A., Fukushima, S., Fujimura, T., Ito, T., Imafuku, K., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15151 · Cited by 52
Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma
Braune, J., Keller, L., Schiller, F., Graf, E., Rafei-Shamsabadi, D. A., Wehrle, J., Follo, M., Philipp, U., Hussung, S., Pfeifer, D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00174 · Cited by 55
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 53
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 59
“Currently, ICIs are being evaluated in clinical trials for various types of tumors, including melanoma [6,7], non-small cell lung cancer (NSCLC) [8,9], renal cell carcinoma (RCC) [10], uroepithelial cancer (UC) [11], and head and neck squamous cell carcinoma (HNSCC) [12] (Table 1).”
BackgroundSamimi, M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00427-9 · Cited by 51
Silva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 50
“The introduction of the less toxic and more effective Abs targeting PD-1 and its ligand PD-L1 has limited the appeal of using anti-CTLA-4 Abs as single agents in advanced melanoma.(22) A combinational strategy including the administration of anti-CTLA-4”
BackgroundAscierto, P. A., Lewis, K. D., Giacomo, A. M. D., Демидов, Л. В., Mandalà, M., Bondarenko, I., Herbert, C., Mackiewicz, A. A., Rutkowski, P. L., Guminski, A. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.002 · Cited by 51
Self-citationMelanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Testa, U., Castelli, G., & Pelosi, E. (2017) · Medical Sciences · doi:10.3390/medsci5040028 · Cited by 59
“Among patients undergoing resection of stage III or IV melanoma, immunotherapy based on nivolumab administration resulted in a higher level of recurrence-free survival and a lower rate of grade 3 or 4 toxic events than immunotherapy based on ipilimumab administration [294].”
BackgroundNinomiya, K., Oze, I., Kato, Y., Kubo, T., Ichihara, E., Rai, K., Ohashi, K., Kozuki, T., Tabata, M., Maeda, Y., et al. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1695062 · Cited by 54
“Furthermore, CTLA-4 inhibitors are more toxic than PD-1 inhibitors [62], suggesting that it may have been poorly tolerated for elderly patients with comorbidities.”
BackgroundModern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
Petrova, V., Arkhypov, I., Weber, R., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072367 · Cited by 54
“In cases of resectable melanoma, anti-PD1 agents are prescribed as well in an adjuvant setting [22].”
BackgroundRecent Developments of Systemic Chemotherapy for Gastric Cancer
Arai, H., & Nakajima, T. E. (2020) · Cancers · doi:10.3390/cancers12051100 · Cited by 51
“However, the adjuvant use of ICIs, such as nivolumab (anti-PD-1 antibody) and ipilimumab (anti-CTLA-4 antibody), has shown significant benefit in reducing recurrence in resected melanoma [58,59].”
BackgroundKönig, D., & Laubli, H. P. (2020) · Pharmacology · doi:10.1159/000509081 · Cited by 54
Eggermont, A. M. M., Bellomo, D., Arias‐Mejias, S. M., Quattrocchi, E., Damodaran, S. S., Bridges, A. G., Lehman, J. S., Hieken, T. J., Jakub, J. W., Murphree, D. H., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.029 · Cited by 52
Huang, Y., Zhu, L., Guo, T., Chen, W., Zhang, Z., Li, W., & Pan, X. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1823779 · Cited by 52
“resectable melanoma significantly prolonged PFS and reduced the incidence of grade 3 to 4 adverse reactions.(55) More recently, Warner et al.”
BackgroundRNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells
Zhang, Z., Kong, X., Ligtenberg, M. A., Veen, S. E. V. H.-V., Visser, N. L., de Bruijn, B., Stecker, K. E., van der Helm, P. W., Kuilman, T., Hoefsmit, E. P., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100655 · Cited by 57
“Immune checkpoint blockade (ICB) and adoptive T cell transfer therapies serve to (re-)invigorate tumor-specific CD8 T cell function.(1,2) However, for melanoma, but more frequently for other cancer indications, either primary or acquired resistance limits overall and durable patient benefit.”
BackgroundDóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 51
“significant difference in progression-free survival (PFS) in metastatic melanoma patients with any grade of irAEs [55].”
BackgroundLiu, N., Zhang, J., Yan, M., Chen, L., Wu, J., Tao, Q., Yan, B., Chen, X., & Peng, C. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05692-5 · Cited by 52
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 52
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma
Gaiser, M. R., Bongiorno, M. A., & Brownell, I. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445966 · Cited by 53
LoConte, N. K., Gershenwald, J. E., Thomson, C. A., Crane, T. E., Harmon, G. E., & Rechis, R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200093 · Cited by 55
Nivolumab and Ipilimumab: Immunotherapy for Treatment of Malignant Melanoma
Carreau, N. A., & Pavlick, A. C. (2018) · Future Oncology · doi:10.2217/fon-2018-0607 · Cited by 49
Audrito, V., Managò, A., Gaudino, F., & Deaglio, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.001 · Cited by 51
Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma
Mitra, S., Lauss, M., Cabrita, R., Choi, J., Zhang, T., Isaksson, K., Olsson, H. L., Ingvar, C., Carneiro, A., Staaf, J., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12663 · Cited by 58
“…checkpoint inhibitors (ICIs), such as CTLA4 and PD1/PDL1 blockade, that reactivate tumor-associated effector T cells have demonstrated dramatic clinical efficacy and provide long-term survival in a substantial fraction of patients (Hodi et al., 2010; Weber et al., 2015, 2017; Wolchok et al., 2017).”
BackgroundRoles for receptor tyrosine kinases in tumor progression and implications for cancer treatment
Ghosh, S., Marrocco, I., & Yarden, Y. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.002 · Cited by 58
The ups, downs and new trends of IDO1 inhibitors
Chen, S., Tan, J., & Zhang, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104815 · Cited by 49
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.